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To compare the eﬃcacy and safety of mebendazole and secnidazole in the treatment of giardiasis in adult patients, a single-
centre, parallel group, open-label, randomized non-inferiority trial was carried out. One-hundred and 26 participants who had
symptomatic Giardia mono-infection took part in the study. Direct wet mount and/or Ritchie concentration techniques and
physical examinations were conducted at the time of enrolment and at the follow-up visit. The primary outcome measure was
parasitological cure, performed at 3, 5, 10 days post-treatment. Negative faecal specimens for Giardia were ensured by the same
parasitological techniques. At follow up (day 10) the parasitological cure rate for the per protocol populations was 88.7% (55/62)
forMBZand91.8%(56/61)forSNZ.Fortheintentiontotreatpopulationsthecurerateattheendoftreatmentwas85.9%(55/64)
for MBZ and 90.3% (56/62) for SNZ. Both analyzes showed there was not signiﬁcant statistical diﬀerence between MBZ and SNZ
treatment eﬃcacy. Both drugs were well tolerated, only mild, transient and self-limited side eﬀects were reported and did not
require discontinuation of treatment. A 3-day course of mebendazole seems to be as eﬃcacious and safe for treatment of giardiasis
as a single dose of secnidazole in adults.
1.Introduction
Giardialamblia,thecausativeagentofgiardiasis,isoneofthe
commonest intestinal parasitic protozoan infections diag-
nosed world-wide. The spectrum of this infection may range
from asymptomatic shedding of giardial cysts to symptoma-
tic giardiasis, being responsible for abdominal cramps, nau-
sea,acuteorchronicdiarrhoea,withmalabsorption,andfail-
ure of children to thrive [1].
Five nitroimidazole compounds are considered to be the
ﬁrst-line regular therapy for this infectious disease. However,
whilst their therapeutic beneﬁts are generally accepted, treat-
ment failures are often reported [2, 3], and that is why a vari-
ety of new approaches to the treatment of giardiasis have
been entering into clinical practice [4].
Evidencefromuncontrolledcaseseriesandclinicaltrialsin
paediatric patients suggests that mebendazole (MBZ) might
have a role in the treatment in this parasitosis and that its
therapeutic eﬀect is achieved without an accompanying in-
crease of side eﬀects [5–8]. Despite the number of articles
published concerning the use of this drug in paediatric pa-2 Journal of Parasitology Research
tients with giardiasis, the information about the use of MBZ
in adult giardiasis is scarce.
TheaimofthestudywastodeterminewhetherMBZisas
eﬃcacious and safe as secnidazole (SNZ), a 5-nitroimidazole
with a high rate of healing and low cost, in the treatment of
adult patients with giardiasis.
2.SubjectsandMethods
2.1. Study Design and Patients. A single-centre, randomised,
unblinded, parallel-group, open-labeled, no-inferiority clin-
ical trial was carried out at “Carlos J. Finlay” Hospital in
Havana City, Cuba. The study protocol was reviewed and ap-
proved by the institutional review board of the hospital.
The study subjects were adult patients (17 years old or
older)whohad beenreferredbygeneralpractitioners orwho
presented at the hospital seeking treatment for symptomatic,
acute G. lamblia monoinfection (proven by microscopical
examination of faecal samples as direct wet mounts and/or
after Ritchie concentration). Patients were not allowed to
participate if they had previously received any antiparasitic
drug within 1 month before entering the study. Other exclu-
sion criteria had known hypersensitivity to any of the drugs
in use and suspected immunodeﬁciency, had hepatic, renal,
cardiovascular, or haematological disease, and had concomi-
tant use of other drugs. Women were ineligible if they were
pregnant or lactating. Women of childbearing potential were
only admitted if they were using safe, adequate, and medical-
ly accepted contraceptive precautions. Patients fulﬁlling the
inclusion criteria received written and oral information on
the aims of the study before asking for their participation
decision. Enrolment was also dependent on the production
of an informed consent form signed. The speciﬁc objectives
were to determine the parasitological answer of the patients
once they took MBZ or SNZ and to identify and evaluate
theintensityofthepossibleadverseeventsoncepatientstook
MBZ or SNZ.
It was considered that the experimental treatment with
MBZ was not inferior to the treatment with SNZ if the pro-
portion of the patients cured parasitologically with MBZ was
20% less than the proportion of the patients cured with the
therapeutic with SNZ. The sample size was estimated for the
two treatment groups (n), based on the assumption: a res-




one of the two parallel groups. A randomized list of two in-
diﬀerent blocks was generated automatically by a computer
to assign the patients to one or another group of treatment.
Medical doctors whose assisted the patients carried out the
assignation according to the list conformed to receive either
MBZ (200mg three times daily for 3 days, according with
earliertrialsinwhich200mgthreetimesdailyfor3dayspro-
duced 78% parasitological cure rates in children) [7]o rS N Z
(2g as a single dose).
Clinical signs and symptoms were recorded in a written
evaluationformforeachpatientatthebeginningofthestudy
period through the interrogatory in the place of the consul-
tation. Adverse events, deﬁned as signs and symptoms that
ﬁrst occurred or became more severe following the treat-
ment,wererecordedusingastandardizedquestionnaire,tak-
ing into account its intensity and duration. The events are
classiﬁed as mild: occasional event without normal activities
interferences; moderate: events where there are normal acti-
vities interferences, but occasional; serious: those adverse
events that required hospitalisation, were life threatening, or
resulted in a persistent or signiﬁcant disability or death.
2.2.Followup. Theeﬃcacyofthechemotherapy wasassessed
by the microscopical examination (as direct wet mount and
Ritchie concentration) of faecal samples collected soon (3,
5, and 10 days) after treatment completion in order to avoid
thebiasthatwouldbeintroducedbyreinfection.Patientsand
physicians knew the treatment assignment; nevertheless, the
laboratory personnel who analysed the faecal samples to
determinetheparasitologicaloutcomewereblindtopatient’s
treatment assignment. The patient was only considered to be
cured if no Giardia cysts or trophozoites could be found in
any of the three posttreatment faecal samples. Patients were
evaluated again to ask about their symptoms and signs once
they had the results of their faecal samples after the treat-
ment.
Criteria for patient withdrawal from the study included
(a) the patient’s desire to withdraw from the study; (b) vio-
lation of the study protocol; (c) onset of a serious medical
condition.
2.3. Statistical Analysis. Baseline characteristics and adverse
events were compared using χ2 tests in categorical data, for
continuous data Student’s t-test was used.
The hypothesis test for proportion equivalence and the
associated 2-sided 95% CI for the diﬀerence was estimated to
evaluate the equivalence of the principal variable “parasito-
logical eﬃcacy” and it was carried on by intention to treat as
if as per protocol [9, 10]. The no-inferiority margin deﬁned
intheprimaryanalysiswasbasedonabsolutecureratediﬀer-
ences. No inferiority of MBZ over SNZ was accepted [in a
two-side 0.05 level test] if the upper bound of the 95% CI
around the estimated diﬀerence in parasitological cure rates
lies below 20%.
3. Results
3.1. Patient Characteristics. From March 2005 through Feb-
ruary, 2006 a total of 163 patients presenting to the trial site
were screened and 126 were eligible and agreed to be enroll-
ed; 123 of them successfully completed the study (Figure 1).
In the research, the eﬃcacy and safety analysis was done per
protocol aswellasbyintentiontotreat.Baselinedemographic
characteristics are summarised in Table 1. Overall, there was
a slightly higher proportion of males compared to females
entering the study (69% versus 30.9%); however, there were
no signiﬁcant diﬀerences between the groups concerning
gender distribution neither in terms of age (P>0.05). Con-
cerning clinical features, nausea was the only one that wasJournal of Parasitology Research 3
Table 1: Baseline characteristics of the patients.
MBZ SNZ
Characteristic n = 64 n = 62
No. (%) No. (%)
Gender
Male 45 (70.3) 42 (67.7)






Abdominal pain 42 (65.6) 47 (75.8)
Diarrhoea 13 (20.3) 12 (19.2)
Lost of appetite 12 (18.7) 13 (20.9)
Nausea 7 (10.9) 16 (25.8)
Flatulence 5 (7.8) 4 (6.5)
163 patients assessed for eligibility
37 excluded from screening
22 not meeting inclusion criteria
126 randomized
64 assigned to receive MBZ 62 assigned to receive SCN
2 withdrew
2 lost to follow up
1 did not bring the
faecal sample
62 completed trial 61 completed trial
64 included in the
analysis
62 included in the
analysis
Figure 1: Flow diagram of the clinical trial progress.
more reported by patients who would receive SNZ and had
statistically signiﬁcant diﬀerence (P<0.05).
3.2. Eﬃcacy Assessment. Table 2 displays the eﬃcacy results.
No inferiority was found for both kinds of analysis, per pro-
tocol and intention to treat. At followup, parasitological cure
showed by per-protocol analysis was experienced by 88.7%
(55/62)and91.8%(56/61)ofthepatientstreatedintheMBZ
and SNZ groups, respectively. This gave an absolute diﬀeren-
ce of 3.1% (two-side 95% IC −1; 0.12); and P value associa-4 Journal of Parasitology Research
Table 2: Parasitological response and adverse events reported after treatment.
MBZ SNZ Estimated diﬀerences 95% IC of diﬀerence (I1−α)
No. % No. % between MBZ-SNZ [−1,Ps − Pe +Z1−α
∗SE]
Eﬃcacy
Patients with parasitological cure
∗55/64 85.9 56/62 90.3 −4.4% [−1,0.14]
∗∗55/62 88.7 56/61 91.8 −3.1% [−1,0.12]
Safety
Patients with at least one adverse
event 15/64 23.4 20/62 32.3 −8.9% (−26.0;8.4)
Type of events adverse reported
Abdominal pain 12 (18.7) 14 (22.6)
Nausea 5 (7.8) 4 (6.4)
Bitter taste 2 (3.1) 15 (24.1)
Diarrhoea 2 (3.1) 3 (4.8)
Dizziness 0 (0) 6 (9.6)
∗Intention-to-treat analysis for the no inferiority.
∗∗Per-protocol analysis for the no inferiority.
tedof0.0008.Whenwereincludedallrandomizedpatientsin
intention-to-treat analysis, the cure rates at the end of treat-
ment were 85.9% (55/64) for MBZ and 90.3% (56/62) for
SNZ, the two-sided 95% IC −1; 0.14; P = 0.003. Both anal-
yses show the upper limit IC for the population proportion
diﬀerence was lesser than 0.2, the diﬀerence chosen.
3.3. Safety Assessment. No patients in any treatment group
discontinued the study due to adverse events. Adverse events
during treatment are shown in Table 2. Both drugs were well
tolerated; only mild, transient, and self-limited adverse
events were reported; most of them developed between 30
minutes and six hours after treatment but had subsided
within 24 hours. There was no statistically signiﬁcant diﬀer-
ence between the total numbers of patients who experienced
anadverseeventinthetwotreatmentgroups.Theeventmost
commonlyreportedinMBZtreatmentgroupwasabdominal
pain [12/64, (18.7%)] versus 22.5% in the SNZ treatment
group. Apart from bitter taste and dizziness, which were
more frequently reported amongst those who took SNZ and
had statistically signiﬁcant diﬀerences, there were no statisti-
cally signiﬁcant diﬀerences in the report of any of the other
adverse events reported.
4. Discussion
The present study gives additional information about the use
of MBZ in the treatment of adult patients with giardiasis.
Despite initial studies carried out by Hutchison et al. in 1975
[11] which had demonstrated the eﬀectiveness of MBZ in
the treatment of Giardia infection, the full potential of this
alternative regimen was not immediately apparent. It could
be due, in part, because there has been some debate concern-
ing to the eﬃcacy of this drug in this indication; while Al-
Waili and Hasan [12]r e p o r t e dah i g hGiardia eradication
with this drug, Gascon et al. [13] and di Martino et al. [14]
failed to clear parasitic infection or symptoms in their pa-
tients. In vitro studies in which it has been demonstrated that
MBZ at low concentrations (0.05 micrograms/mL) has a
static eﬀect on G. lamblia growth and has a lethal activity at
a concentration ﬁvefold lower (0.3 micrograms/mL) than
that necessary for metronidazole have also led to the present
situation where MBZ is recognized to play an important role
in the treatment of giardiasis [15].
In paediatric practice, MBZ has been used as an eﬃca-
cious and safe treatment option. A number of studies have
been performed in children comparing this drug with some
of the currently available antigiardial drugs. An overall anal-
ysisoftheresultsshowsthatMBZpossessesaneﬃcacywhich
is comparable to secnidazole 30mg as a single dose (78.1%
versus 79.4%) [7], to that of a 7-day course of metronidazole
(86%versus90%)[8],andtothatachievedwith3-daycourse
of nitazoxanide (71% versus 75%) and also equivalent to 5-
daycourseofquinacrine(78.7%versus83.6%)[5].However,
the eﬃcacy of 600mg of MBZ divided into three doses, in a
singleday,wassigniﬁcantlylowerthan50mg/kgoftinidazole
takenasasingledose(63.9%versus81.9%)[6].Nevertheless,
these studies have not only conﬁrmed the potency and safety




as criteria the absence of trophozoites or cysts from treated
patients. It has been demonstrated that MBZ is a suitable
candidatetotreatgiardialinfectionsinadultpatientsasequi-
valent SNZ. While the little eﬃcacy diﬀerence in favour of
SNZ in terms of parasitological cure rates was unsurprising,
it was interesting to note that there was no statistically signi-
ﬁcant diﬀerence between the groups. Also, when adverse
events in general were evaluated, both treatments were well
tolerated with similar adverse event proﬁles; however, there
was an advantage with MBZ. This drug was well tolerated as
well as eﬃcacious. In no case did side eﬀects lead to discon-
tinuation of the treatment. The most frequently reportedJournal of Parasitology Research 5
adverse event was abdominal pain, which was not unexpect-
ed taking into account previous articles reported in children
[5–8]. These ﬁndings are consistent with clinical experience
with MBZ. Even in studies when this drug has been used in
higher doses, in divided doses after fat-rich meals, and for
the treatment of the hydatid disease, there is little evidence
of systemic eﬀects, suggesting that MBZ has a wide margin
between its antigiardial therapeutic eﬀects and its adverse
events [16], which seems to be conﬁrmed by Rippmann
et al. [17] and Franchi et al. [18]. Studies have shown that
MBZ is relatively poorly absorbed from gastrointestinal tract
[19].
While SNZ oﬀers the advantage of single-dose therapy
andhigherrateofeﬃcacy,MBZhasalsotheadvantageofless
frequent dosing than metronidazole, other 5-nitroimidazole
very frequently used, and shorter duration of therapy and, at
the same time, is better tolerated, factors associated with im-
proved treatment compliance. The simplicity of the SNZ
treatment must be placed in one side of the balance, resting
in the other side adverse events as bitter taste which was
signiﬁcantly reported in this group of treatment and is relat-
ed with this and other 5-nitroimidazolic drugs and the possi-
bility of therapeutic failures.
Accordingtotheresultsobtained,MBZappearstobealso
an important option for the treatment of G. lamblia infec-
tions in adults, too. Together, with the beneﬁcial therapeutic
eﬀect, several other characteristics of MBZ may enhance its
potential to giardiasis therapy, ﬁrst, for patients intolerant to
5-nitroimidazole compounds. Second, the use of this drug
has lower incidence of mild and self-limited adverse events,
may be due to its poor absorption from the gastrointestinal
tract, the lack of interference with the balance of the micro-
bial ecosystem of the gut, and the possibility of clearing or
reduceingtheparasiticburdenofsomeofthecommonintes-
tinal helminths which may co-occur, reducing at the same
time the environment contamination with eggs of other sen-
sitive organisms, for example, intestinal nematodes, which
are especially frequent in tropical climates throughout the
world. All of these pinpoint MBZ as a wise treatment option
in multiple clinical settings.
We consider that MBZ has its role in the antigiardial
armamentarium and should be considered as an alternative,
especially when ﬁrst-line drugs have failed, were not toler-
ated, or are not available. Also, MBZ could be possibly taken
as adjunctive therapy in combination with other available
antigiardial drugs targeting diﬀerent pathways in order to
oﬀer potentially higher cure rates. This seems to be a pro-
mising task and would provide a focus for future studies. It
is also important that the good clinician strives to achieve an
overview of the beneﬁcial eﬀects of this treatment option in
a given patient, taking into account all of the various drug
eﬀects for which a patient would be beneﬁted and put it into
a balance with the other drugs currently in use for giardiasis.
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